Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 19.7% in March

Jasper Therapeutics, Inc. (NASDAQ:JSPR) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 1,670,000 shares, a decline of 19.7% from the February 28th total of 2,080,000 shares. Approximately 14.1% of the company’s shares are sold short. Based on an average trading volume of 526,700 shares, the short-interest ratio is currently 3.2 days.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $4.14 on Wednesday. Jasper Therapeutics has a 1 year low of $4.11 and a 1 year high of $30.70. The stock has a 50-day simple moving average of $5.63 and a 200-day simple moving average of $14.47. The stock has a market capitalization of $62.19 million, a P/E ratio of -0.87 and a beta of 2.23.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.35). Analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Trading of Jasper Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its position in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after acquiring an additional 1,698 shares in the last quarter. MetLife Investment Management LLC grew its holdings in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares in the last quarter. Wells Fargo & Company MN increased its stake in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after buying an additional 3,828 shares during the period. EntryPoint Capital LLC purchased a new stake in Jasper Therapeutics during the 4th quarter worth $223,000. Finally, Tema Etfs LLC acquired a new position in Jasper Therapeutics in the 4th quarter worth $266,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JSPR has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. JMP Securities restated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. UBS Group assumed coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $38.00 price objective on the stock. Royal Bank of Canada decreased their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. Finally, BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $62.50.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.